Dr Reddy's sees FY2011/12 sales rise 30%

India’s second-largest drugmaker, Dr Reddy’s Laboratories (NYSE: RDY) posted full year ended March 31, 2012 financial results, with consolidated sales up 96.7 billion rupees ($1.8 billion at current exchange rates but over $2 billion at average rates for the reporting year), a rise of 30% on the previous fiscal year, driven by its key markets of North America and Russia in the global generics segment and Pharmaceutical Services and active ingredients segment.

EBITDA of 25.4 billion rupees represented 26% of revenue and 51% year-on-year growth. Profit after Tax was 15.3 billion rupees, year-on-year growth of 42%. The board of directors has proposed a dividend of 13.75 rupees (275%) per equity share of 5 rupees face value, subject to the approval of shareholders.

During the year, the company launched 141 new generic products, filed 88 new product registrations and filed 68 Drug Master Files (DMF) globally.